[3H]TAK-875 (fasiglifam), which is a small molecule FFAR1 agonist that reached clinical phase 3, exhibited high non-specific off-target binding in insulinoma xenograft tissue, demonstrating the difficulties involved in molecular imaging with lipophilic compounds (Fig. 2). Here, FFAR1 is linked to pancreatic insulinoma.